Study on the Mechanisms of Banxia Xiexin Decoction in Treating Diabetic Gastroparesis Based on Network Pharmacology
- PDF / 3,718,343 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 36 Downloads / 157 Views
ORIGINAL RESEARCH ARTICLE
Study on the Mechanisms of Banxia Xiexin Decoction in Treating Diabetic Gastroparesis Based on Network Pharmacology Tingchao Wu1 · Rensong Yue1 · Liang Li2 · Mingmin He1 Received: 28 February 2020 / Revised: 25 August 2020 / Accepted: 31 August 2020 © International Association of Scientists in the Interdisciplinary Areas 2020
Abstract In China, Banxia Xiexin decoction (BXD) is applied to treat diabetic gastroparesis (DGP), but its key active ingredients and mechanisms against DGP are unclear. This study is designated to reveal the molecular mechanisms of BXD in treating DGP by adopting a creative approach known as network pharmacology to explore the active ingredients and therapeutic targets of BXD. In our study, 730 differentially expressed genes of DGP were obtained, and 30 potential targets of BXD against DGP were screened out (including ADRB2, DRD1, FOS, MMP9, FOSL1, FOSL2, JUN, MAP2, DRD2, MYC, F3, CDKN1A, IL6, NFKBIA, ICAM1, CCL2, SELE, DUOX2, MGAM, THBD, SERPINE1, ALOX5, CXCL11, CXCL2, CXCL10, RUNX2, CD40LG, C1QB, MCL1, and ADCYAP1). Based on the findings, BXD contains 60 compounds with therapeutic effect on DGP, including the key active ingredients such as quercetin, wogonin, baicalein, beta-sitosterol, and kaempferol. Sixty-eight pathways including TNF signaling pathway, IL-17 signaling pathway, and AGE-RAGE signaling pathway were significantly enriched. In this study, the mechanisms of BXD in treating DGP are affirmed to be a complex network with multi-target and multi-pathway, which provides a reference for future experimental studies. Keywords Banxia Xiexin decoction · Diabetic gastroparesis · Network pharmacology · Traditional Chinese Medicine
1 Introduction Diabetic gastroparesis (DGP) is one of the common diabetic autonomic neuropathies characterized by non-obstructive delayed gastric emptying [1], which was first reported by Kasander in 1958 [2]. This disease is clinically manifested by upper abdominal distension, pain and discomfort, early satiety, postprandial fullness, belching, nausea, emesis, and poor appetite [3], but its epidemiological data are limited. It is reported that about 30–50% of the diabetic patients has a long history of gastroparesis [4]. According to the sole epidemiological survey on diabetic and non-diabetic gastroparesis, 46% of gastroparesis patients suffer DGP [5, 6]. Current researches indicate that DGP is closely related to poor glycemic control, frequent hypoglycemia, decreased quality * Rensong Yue [email protected] 1
Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi‑er‑qiao Road, Chengdu 610072, SiChuan, China
University of Electronic Science and Technology of China, Chengdu, SiChuan, China
2
of life, and increased medical expenses [7–10]. The pathogenesis of DGP is unclear yet, but the general opinion is that it may be concerned with autonomic nervous dysfunction, abnormal secretion of gastrointestinal hormones, decrease in interstitial cells of Cajal (ICCs), change in immune cell functions, and
Data Loading...
